Farrell, Michael, Shahbazi, Jeyran, Byrne, Marianne, Grebely, Jason, Lintzeris, Nicholas, Chambers, Mark, Larance, Briony, Ali, Robert, Nielsen, Suzanne, Dunlop, Adrian, Dore, Gregory J., McDonough, Michael, Montebello, Mark, Nicholas, Thomas, Weiss, Rob, Rodgers, Craig, Cook, Jon, Degenhardt, Louisa. Elsevier; 2022. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

Farrell, Michael, Shahbazi, Jeyran, Nielsen, Suzanne, Dunlop, Adrian, Dore, Gregory J., McDonough, Michael, Montebello, Mark, Weiss, Rob, Rodgers, Craig, Cook, Jon, Degenhardt, Louisa, Chambers, Mark, Byrne, Marianne, Gholami, Jaleh, Zahra, Emma, Grebely, Jason, Lintzeris, Nicholas, Larance, Briony, Ali, Robert. Elsevier; 2024. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.

Settumba, Stella, Shahbazi, Jeyran, Blazey, Alison, Weiss, Robert, Dunlop, Adrian, McDonough, Michael, Cook, Jon, Farrell, Michael, Byrne, Marianne, Degenhardt, Louisa, Grebely, Jason, Larance, Briony, Nielsen, Suzanne, Lintzeris, Nicholas, Ali, Robert, Rodgers, Craig. Wiley-Blackwell; 2025. Provider costs of treating opioid dependence with extended-release buprenorphine in Australia.